dew-logo.png
Dew Aesthetics Unveils Cutting-Edge MedSpa Treatments in Baltimore, Pioneering a Path to Timeless Beauty
May 15, 2024 10:00 ET | Dew Aesthetics
BALTIMORE, Md., May 15, 2024 (GLOBE NEWSWIRE) -- Dew Aesthetics, the premier destination for cutting-edge medical spa treatments, is proud to announce the launch of its innovative services,...
Pacific Software Inc. Secures Strategic License Agreement with the University of California for Innovative Technology for Stimulating Collagen Production
May 15, 2024 09:00 ET | Pacific Software Inc.
Pacific Software Inc. partners with UCI to launch Dermatrix™, a revolutionary collagen-boosting peptide for cosmetics and wound healing.
Logo.png
GRI Bio to Present at Alliance Global Partner’s 2024 Healthcare Company Showcase
May 14, 2024 09:05 ET | GRI Bio, Inc.
Live webcast fireside chat on Tuesday, May 21st at 2:40 PM ET LA JOLLA, CA, May 14, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company...
Picture1.jpg
ONCOTELIC PRESENTING AT BIOPHARMA NEXUS CONFERENCE SAN DIEGO 2024
May 08, 2024 08:00 ET | Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its presentation at Biopharma Nexus Conference. Dr. Andy Hu, Nanomedicine Manager,...
Palisade Bio_Logos(4.22)VSM.png
Palisade Bio Announces Closing of $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules
May 07, 2024 07:30 ET | Palisade Bio, Inc.
Carlsbad, CA, May 07, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with...
Pacific Software Inc. Announces a Landmark Asset Acquisition from Dreamaderm Inc.
May 06, 2024 08:00 ET | Pacific Software Inc.
Pacific Software acquires Dreamaderm assets, including Dermatrix, a peptide-enhancing cosmeceutical for diverse dermatological applications.
IMG_5056
Derm-Biome Pharmaceuticals’ topical therapy shows positive results in preclinical skin cancer trial: drug prevents the development of precancerous skin conditions and treats existing skin cancers with no observable side effects. 
April 17, 2024 10:15 ET | Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, April 17, 2024 (GLOBE NEWSWIRE) -- The rates of precancerous skin conditions and skin cancers are soaring in many parts of the world. Actinic keratosis (AK) is the most...
logo.png
Autonomix Announces Issuance of U.S. Patent Covering Proprietary Catheter-Based Technology for the Treatment of Cancer Related Pain
April 16, 2024 09:00 ET | Autonomix Medical, Inc.
Patent portfolio with over 100 patents, issued and pending, protects technology targeting a $100 billion market opportunity Company developing potential breakthrough two-fold technology that can...
cmi_logo.png
[Latest] Global Lung Tumor Market Size/Share Worth USD 46.3 Billion by 2033 at a 7.7% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
April 15, 2024 12:30 ET | Custom Market Insights
Austin, TX, USA, April 15, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Lung Tumor Market Size, Trends and Insights By Product (Imaging systems, Biopsy...
tiziana-logo.png
Tiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology
April 11, 2024 07:00 ET | Tiziana Life Sciences Ltd.
Tiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the American Academy of Neurology